For the quarter ended June 30, 2026, reported on August 13, 2026, revenue rose 145% year over year and 60% sequentially, or 73% excluding a presentation change.Gross Profitwas USD 766 thousand, a calculated grossMarginof 5.1%, down from USD 1.9 million in the first quarter. …
In the quarter ended June 30, 2026, revenue was USD 47.0 million, down 1% from USD 47.6 million, while gross profit fell to USD 15.8 million, a 34%Marginversus 55% a year earlier. Adjusted EBITDA was USD 5.7 million against USD 18.1 million, and net …
The Rationale: Last Reported Quarter and Management Outlook for Smith-Midland Corporation (NASDAQ:SMID)
The Rationale: Last Reported Quarter and Management Outlook for Unicycive Therapeutics, Inc. (NASDAQ:UNCY)
The Rationale: Last Reported Quarter and Management Outlook for NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)
In the quarter ended June 30, 2026,Gross Profitrose 16% to USD 8.8 million, income from operations was USD 967 thousand against a loss of USD 171 thousand, andNet Incomewas USD 37 thousand. After USD 986 thousand of preferred dividends paid in kind, the loss …
The Rationale: Last Reported Quarter and Management Outlook for Wrap Technologies, Inc. (NASDAQ:WRAP)
Key Highlights65% is the year-over-yearRevenuegrowth FitLife Brands, Inc. (NASDAQ:FTLF) reported for the quarter ended June 30, 2026, lifting revenue to USD 26.5 million from USD 16.1 million, mainly because of the Irwin Naturals acquisition.37.0% is the grossMarginFitLife Brands, Inc. (NASDAQ:FTLF) posted in the second …
The Rationale: Last Reported Quarter and Management Outlook for Insight Molecular Diagnostics (NASDAQ:IMDX)
The net loss for the first half of 2026 was USD 34,177,639, of which USD 31,643,299 was attributable to Venu. Basic and diluted loss per common share was USD 0.60 on 53,302,185 weighted average common shares. The company has not issued numeric financial guidance. …